Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 15
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with high-risk uveal melanoma who would receive nivolumab and ipilimumab before surgery.

Age

18 years or older

Sex

All sexes can join.

Disease stage

High-risk uveal melanoma

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details